SISU PHARMA, INC.
EXPLOITING THE STRESS PROTECTION RESPONSE
Sisu Pharma exploits cellular stress by directly targeting the transcription factor Heat Shock Factor 1 (HSF1), the Central Regulator of the heat shock response. Our HSF1 targeting platform (HI-LiTe) is being leveraged to deliver selective HSF1 degraders for oncology. Sisu’s first-in-class compounds demonstrate compelling efficacy in therapy-resistant cancer models where all current treatments fail. The platform provides additional opportunities to develop therapies for use in neurodegenerative conditions and infection, providing a unique approach to treating these devastating diseases.
![Picture1](https://sisupharma.com/wp-content/uploads/2023/02/Picture1.png)
FOUNDERS AND SCIENTIFIC ADVISORY BOARD
Sisu Pharma is led by a team of world-class scientists with decades of experience and success in basic and translational oncology research and FDA-approved cancer drug development
![staff4](https://sisupharma.com/wp-content/uploads/2023/02/staff4-260x296.png)
Sean E. O’Brien, Ph.D.
Founder, Chief Executive Officer
![staff1](https://sisupharma.com/wp-content/uploads/2023/02/staff1-260x296.png)
Dennis J. Thiele, Ph.D.
Founder, Chief Scientific Officer, Member Scientific Advisory Board
![staff2](https://sisupharma.com/wp-content/uploads/2023/02/staff2-260x296.png)
Jiaoti Huang, M.D. Ph.D.
Founder, Chair Scientific Advisory Board
![Mike_orig_BW](https://sisupharma.com/wp-content/uploads/2023/04/Mike_orig_BW-225x239.jpg)